Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
12,214
archived clinical trials in
Women's Studies

Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer
A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen
Status: Enrolling
Updated:  12/31/1969
CCOP - MainLine Health
mi
from
Wynnewood, PA
Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer
A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen
Status: Enrolling
Updated: 12/31/1969
CCOP - MainLine Health
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer
A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen
Status: Enrolling
Updated:  12/31/1969
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer
A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen
Status: Enrolling
Updated: 12/31/1969
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer
A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen
Status: Enrolling
Updated:  12/31/1969
Veterans Affairs Medical Center - Tennessee Valley Healthcare System - Nashville Campus
mi
from
Nashville, TN
Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer
A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen
Status: Enrolling
Updated: 12/31/1969
Veterans Affairs Medical Center - Tennessee Valley Healthcare System - Nashville Campus
mi
from
Nashville, TN
Click here to add this to my saved trials
Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer
A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen
Status: Enrolling
Updated:  12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer
A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen
Status: Enrolling
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer
A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen
Status: Enrolling
Updated:  12/31/1969
Veterans Affairs Medical Center - Madison
mi
from
Madison, WI
Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer
A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen
Status: Enrolling
Updated: 12/31/1969
Veterans Affairs Medical Center - Madison
mi
from
Madison, WI
Click here to add this to my saved trials
Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer
A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer
A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Does Enhancing Maternal Peer Interactions Decrease Rates of Postpartum Depression?
Does Enhancing Maternal Peer Interactions Decrease Rates of Postpartum Depression?
Status: Enrolling
Updated:  12/31/1969
Penn State Hershey Medical Center
mi
from
Hershey, PA
Does Enhancing Maternal Peer Interactions Decrease Rates of Postpartum Depression?
Does Enhancing Maternal Peer Interactions Decrease Rates of Postpartum Depression?
Status: Enrolling
Updated: 12/31/1969
Penn State Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham
mi
from
Birmingham, AL
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Medical Center - Los Angeles
mi
from
Los Angeles, CA
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Medical Center - Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Olive View - UCLA Medical Center Foundation
mi
from
Sylmar, CA
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Olive View - UCLA Medical Center Foundation
mi
from
Sylmar, CA
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Helen and Harry Gray Cancer Center at Hartford Hospital
mi
from
Hartford, CT
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Helen and Harry Gray Cancer Center at Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
mi
from
New Britain, CT
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
mi
from
New Britain, CT
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Yale Cancer Center
mi
from
New Haven, CT
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Lakeland Regional Cancer Center at Lakeland Regional Medical Center
mi
from
Lakeland, FL
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Lakeland Regional Cancer Center at Lakeland Regional Medical Center
mi
from
Lakeland, FL
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
mi
from
Savannah, GA
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
mi
from
Savannah, GA
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
William Beaumont Hospital - Royal Oak Campus
mi
from
Royal Oak, MI
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
William Beaumont Hospital - Royal Oak Campus
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
University of Mississippi Cancer Clinic
mi
from
Jackson, MS
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
University of Mississippi Cancer Clinic
mi
from
Jackson, MS
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Regional Cancer Center at Singing River Hospital
mi
from
Pascagoula, MS
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Regional Cancer Center at Singing River Hospital
mi
from
Pascagoula, MS
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Saint Louis University Cancer Center
mi
from
Saint Louis, MO
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Saint Louis University Cancer Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Methodist Estabrook Cancer Center
mi
from
Omaha, NE
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Methodist Estabrook Cancer Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Charles M. Barrett Cancer Center at University Hospital
mi
from
Cincinnati, OH
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Charles M. Barrett Cancer Center at University Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Riverside Methodist Hospital Cancer Care
mi
from
Columbus, OH
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Riverside Methodist Hospital Cancer Care
mi
from
Columbus, OH
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Mount Carmel West Hospital
mi
from
Columbus, OH
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Mount Carmel West Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
David L. Rike Cancer Center at Miami Valley Hospital
mi
from
Dayton, OH
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
David L. Rike Cancer Center at Miami Valley Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Cancer Care Associates - Midtown Tulsa
mi
from
Tulsa, OK
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Cancer Care Associates - Midtown Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/31/1969
Women and Infants Hospital of Rhode Island
mi
from
Providence, RI
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/31/1969
Women and Infants Hospital of Rhode Island
mi
from
Providence, RI
Click here to add this to my saved trials
Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
Status: Enrolling
Updated:  12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
Status: Enrolling
Updated: 12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Angiotensin 2 Receptor (AT2R) in Endothelial Cells in Preeclampsia
Angiotensin 2 Receptor (AT2R) Expression/Activation in Endothelial Cells in Preeclampsia
Status: Enrolling
Updated:  12/31/1969
UnityPoint Health-Meriter Hospital
mi
from
Madison, WI
Angiotensin 2 Receptor (AT2R) in Endothelial Cells in Preeclampsia
Angiotensin 2 Receptor (AT2R) Expression/Activation in Endothelial Cells in Preeclampsia
Status: Enrolling
Updated: 12/31/1969
UnityPoint Health-Meriter Hospital
mi
from
Madison, WI
Click here to add this to my saved trials
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated:  12/31/1969
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated: 12/31/1969
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated:  12/31/1969
The Parkinson's & Movement Disorder Institute
mi
from
Fountain Valley, CA
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated: 12/31/1969
The Parkinson's & Movement Disorder Institute
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated:  12/31/1969
USC School of Medicine
mi
from
Los Angeles, CA
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated: 12/31/1969
USC School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated:  12/31/1969
University of Florida
mi
from
Gainesville, FL
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated: 12/31/1969
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated:  12/31/1969
University of Miami
mi
from
Miami, FL
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated: 12/31/1969
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated:  12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated: 12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated:  12/31/1969
University of Iowa
mi
from
Iowa City, IA
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated: 12/31/1969
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated:  12/31/1969
University of Maryland Medical Center
mi
from
Baltimore, MD
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated: 12/31/1969
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated:  12/31/1969
Wayne State University Medical Center
mi
from
Southfield, MI
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated: 12/31/1969
Wayne State University Medical Center
mi
from
Southfield, MI
Click here to add this to my saved trials
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated:  12/31/1969
Albany Medical Center
mi
from
Albany, NY
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated: 12/31/1969
Albany Medical Center
mi
from
Albany, NY
Click here to add this to my saved trials
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated:  12/31/1969
Beth Israel Med Ctr
mi
from
New York, NY
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated: 12/31/1969
Beth Israel Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated:  12/31/1969
Columbia University
mi
from
New York, NY
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated: 12/31/1969
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated:  12/31/1969
Wake Forest University
mi
from
Winston-Salem, NC
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Enrolling
Updated: 12/31/1969
Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials